文献速递精神分裂症与精神病性障碍

日常实践中精神分裂症患者被随机临床试验排除的代表性与结局

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

本研究将随机临床试验(RCT)的排除标准应用于芬兰和瑞典国家登记中持续使用第二代抗精神病药(除外氯氮平)维持治疗12周的精神分裂症谱系障碍患者,发现79%的患者不符合RCT入组条件,主要排除原因为严重躯体合并症和联用抗抑郁药/心境稳定剂,不符合条件者因精神病住院风险高于符合条件者。

要点

  • 芬兰队列79.9%(14221/17801)和瑞典队列78.3%(5839/7458)的患者不符合RCT入组条件。
  • 不符合条件者因精神病住院风险高于符合条件者:芬兰队列18.4% vs 17.2%(HR 1.14,95%CI 1.04-1.24),瑞典队列20.1% vs 14.8%(HR 1.47,95%CI 1.28-1.92)。
  • 因治疗抵抗、迟发性运动障碍和自杀未遂史而不符合条件者住院风险最高,且符合的排除标准越多住院风险越大。

核心结论

  • RCT可能仅代表约五分之一的精神分裂症谱系障碍真实世界人群。
  • 不符合RCT条件的患者在接受维持治疗期间因精神病住院的风险略高于符合条件者。

研究设计与样本

  • 将RCT中用于精神分裂症谱系障碍复发预防的入组标准应用于芬兰和瑞典国家患者登记中的真实世界人群。
  • 纳入门诊连续使用抗精神病药12周的精神分裂症谱系障碍患者,随访至多1年,接受任何第二代抗精神病药(除外氯氮平)维持治疗。
  • 随访截止于治疗中断、加用其他抗精神病药、死亡或数据库链接结束。
  • 芬兰队列n=17801,平均(SD)年龄47.5(13.8)岁,女性8972例(50.4%);瑞典队列n=7458,平均(SD)年龄44.8(12.5)岁,女性3344例(44.8%)。

主要发现

  • 共20060例(79%)精神分裂症谱系障碍患者不符合RCT入组条件(芬兰队列14221/17801[79.9%],瑞典队列5839/7458[78.3%])。
  • 最常见的排除原因为严重躯体合并症和联用抗抑郁药/心境稳定剂。
  • 不符合条件者因精神病住院风险高于符合条件者:芬兰队列18.4% vs 17.2%(HR 1.14,95%CI 1.04-1.24),瑞典队列20.1% vs 14.8%(HR 1.47,95%CI 1.28-1.92)。
  • 因治疗抵抗、迟发性运动障碍和自杀未遂史而不符合条件者因精神病住院风险最高。
  • 两国均观察到符合的排除标准越多,因精神病住院风险越大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent only a part of the real-world population (ie, unselected patients seen in everyday clinical practice), which may result in an efficacy-effectiveness gap. OBJECTIVE: To quantify the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in RCTs, and to explore whether clinical outcomes differ between eligible and ineligible individuals. DESIGN, SETTING, AND PARTICIPANTS: This study applied eligibility criteria typically used in RCTs for relapse prevention in schizophrenia spectrum disorders to real-world populations. Individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden were identified. Individuals who had used antipsychotics continuously for 12 weeks in outpatient care were selected. Individuals were followed up for up to 1 year while they were receiving maintenance treatment with any second-generation antipsychotic (excluding clozapine). Follow-up was censored at treatment discontinuation, initiation of add-on antipsychotics, death, and end of database linkage. MAIN OUTCOMES AND MEASURES: Proportions of RCT-ineligible individuals with schizophrenia spectrum disorders owing to any and specific RCT exclusion criteria. The risk of hospitalization due to psychosis within 1-year follow-up in ineligible vs eligible persons were compared using hazard ratios (HR) and corresponding 95% CIs. RESULTS: The mean (SD) age in the Finnish cohort (n = 17 801) was 47.5 (13.8) years and 8972 (50.4%) were women; the mean (SD) age in the Swedish cohort (n = 7458) was 44.8 (12.5) years and 3344 (44.8%) were women. A total of 20 060 individuals (79%) with schizophrenia spectrum disorders would be ineligible for RCTs (Finnish cohort: 14 221 of 17 801 [79.9%]; Swedish cohort: 5839 of 7458 [78.3%]). Most frequent reasons for ineligibility were serious somatic comorbidities and concomitant antidepressant/mood stabilizer use. Risks of hospitalization due to psychosis was higher among ineligible than eligible individuals (Finnish cohort: 18.4% vs 17.2%; HR, 1.14 [95% CI, 1.04-1.24]; Swedish cohort: 20.1% vs 14.8%; HR, 1.47 [95% CI, 1.28-1.92]). The largest risks of hospitalization due to psychosis were observed in individuals ineligible owing to treatment resistance, tardive dyskinesia, and history of suicide attempts. Finally, with more ineligibility criteria met, larger risks of hospitalization due to psychosis were observed in both countries. CONCLUSIONS AND RELEVANCE: RCTs may represent only about a fifth of real-world individuals with schizophrenia spectrum disorders. Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher risks of admission due to psychosis while receiving maintenance treatment than RCT-eligible patients. These findings set the stage for future studies targeting real-world populations currently not represented by RCTs.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Taipale H, Schneider-Thoma J, Pinzón-Espinosa J, et al. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. JAMA Psychiatry. 2022. PMID: 35080618. doi:10.1001/jamapsychiatry.2021.3990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。